ISCOMATRIX™ adjuvant: An adjuvant suitable for use in anticancer vaccines

Vaccine

Volumn 22, Issue 27-28, 2004, Pages 3738-3743

  Stewart, Trina J ^a   Drane, Debbie ^b   Malliaros, Jim ^b   Elmer, Heidi ^b   Malcolm, Karen M ^a   Cox, John C ^b   Edwards, Stirling J ^b   Frazer, Ian H ^a   Fernando, Germain J P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

Adjuvant; Cancer vaccine; Tumor protection

Indexed keywords

ALUMINUM HYDROXIDE; CANCER VACCINE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; ISCOMATRIX; PROTEIN E6; PROTEIN E7; QUIL A; RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 E6E7 PROTEIN; RECOMBINANT PAPILLOMAVIRUS TYPE 16 E7GST PROTEIN; RECOMBINANT PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; CANCER ANTIBODY; CHOLESTEROL; CHROMIUM; DIAGNOSTIC AGENT; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PHOSPHOLIPID; RECOMBINANT VACCINE; REPRESSOR PROTEIN; SAPONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CANCER; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY; TUMOR MODEL; WART VIRUS; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; CELL LINE; DELAYED HYPERSENSITIVITY; DRUG COMBINATION; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; CANCER VACCINES; CELL LINE; CHOLESTEROL; CHROMIUM RADIOISOTOPES; DRUG COMBINATIONS; FEMALE; HYPERSENSITIVITY, DELAYED; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PHOSPHOLIPIDS; REPRESSOR PROTEINS; SAPONINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS; VACCINES, SYNTHETIC;

EID: 4143066943     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.026     Document Type: Article

References (19)

1. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55(4):2002;244-265
2. Kjaer S.K., van den Brule A.J., Bock J.E., et al. Human papillomavirus - the most significant risk determinant of cervical intraepithelial neoplasia. Int. J. Cancer. 65(5):1996;601-606
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer. 2(5):2002;342-350
4. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63(10):1989;4417-4421
5. Tindle R.W., Frazer I.H. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation. Curr. Top Microbiol. Immunol. 186:1994;217-253
6. Dalsgaard K. Saponin adjuvants. Part 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch. Gesamte. Virusforsch. 44(3):1974;243-254
7. Sjolander A., Drane D., Maraskovsky E., et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine. 19(17-19):2001;2661-2665
8. Morein B., Bengtsson K.L. Functional aspects of iscoms. Immunol. Cell. Biol. 76(4):1998;295-299
9. Fernando G.J., Stewart T.J., Tindle R.W., Frazer I.H. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term. Scand. J. Immunol. 47(5):1998;459-465
10. Tindle R.W., Croft S., Herd K., et al. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin. Exp. Immunol. 101(2):1995;265-271
11. Fernando G.J., Murray B., Zhou J., Frazer I.H. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin. Exp. Immunol. 115(3):1999;397-403
12. Edwards S.J., Margetts M.B., Hocking D.M., Moloney M.B.H., Rothel L.J., Webb E.A. Design of a candidate recombinant therapeutic vaccine for cervical cancer. Recent Res Develop Biotechnol Bioeng. 1:1998;343-356
13. Hilditch-Maguire P.A., Lieppe D.M., West D., Lambert P.F., Frazer I.H. T cell-mediated and non-specific inflammatory mechanisms contribute to the skin pathology of HPV 16 E6E7 transgenic mice. Intervirology. 42(1):1999;43-50
14. + cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J. Immunol. 161(5):1998;2421-2427
15. Fernando G.J., Stenzel D.J., Tindle R.W., Merza M.S., Morein B., Frazer I.H. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine. 13(15):1995;1460-1467
16. Fernando G.J., Tindle R.W., Frazer I.H. T-helper epitopes of the E7 transforming protein of cervical cancer associated human papillomavirus type 18 (HPV18). Virus Res. 36(1):1995;1-13
17. Stewart T.J., Smyth M.J., Fernando G.J., Frazer I.H., Leggatt G.R. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Res. 63(12):2003;3058-3060
18. Clynes R., Takechi Y., Moroi Y., Houghton A., Ravetch J.V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA. 95(2):1998;652-656
19. Cox J.C., Solander A., Barr I.G. ISCOMs and other saponin based adjuvants. Adv. Drug. Deliv. Rev. 32:1998;247-271